Posted by Michael Wonder on 01 Oct 2021
Kite submits supplemental biologics license application to U.S. FDA for earlier use of Yescarta in large B-cell lymphoma
30 September 2021 - Supplemental biologics license application filing based on landmark ZUMA-7 study, the first randomised clinical trial to evaluate CAR T against standard of care in the second-line setting.
Kite, a Gilead Company, today announced that it has submitted a supplemental biologics license application to the U.S. FDA for Yescarta (axicabtagene ciloleucel) to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma in the second-line setting.
